

# Thomas J Polascik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8936246/publications.pdf>

Version: 2024-02-01

138  
papers

5,105  
citations

87723

38  
h-index

95083

68  
g-index

175  
all docs

175  
docs citations

175  
times ranked

4291  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolution of Focal Therapy in Prostate Cancer. <i>Urologic Clinics of North America</i> , 2022, 49, 129-152.	0.8	5
2	Red Blood Cell Distribution Width Is Associated with All-cause Mortality but Not Adverse Cancer-specific Outcomes in Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy: Findings Based on a Multicenter Shared Equal Access Regional Cancer Hospital Registry. <i>European Urology Open Science</i> , 2022, 37, 106-112.	0.2	5
3	Assessment after focal therapy: what is the latest?. <i>Current Opinion in Urology</i> , 2022, 32, 260-266.	0.9	0
4	Available evidence on HIFU for focal treatment of prostate cancer: a systematic review. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2022, 48, 263-274.	0.7	16
5	Device-related complications during renal cryoablation: insights from the Manufacturer and User Facility Device Experience (MAUDE) database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	1
6	Does MRI-guided TULSA provide a targeted approach to ablation?. <i>Nature Reviews Urology</i> , 2021, 18, 5-6.	1.9	1
7	Genetically Informed Prostate Cancer Screening. <i>Urologic Clinics of North America</i> , 2021, 48, 373-386.	0.8	1
8	Oncological and Functional Outcomes of Patients Undergoing Individualized Partial Gland Cryoablation of the Prostate: A Single-Institution Experience. <i>Journal of Endourology</i> , 2021, 35, 1290-1299.	1.1	15
9	Prostate Cancer Focal Therapy Has Made Great Strides and the Future Remains Bright. <i>Oncology</i> , 2021, 35, 269-269.	0.4	1
10	Current state of image-guided focal therapy for prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 701-717.	1.2	8
11	<i>Editorial Comment on: "Ten-Year Experience with Percutaneous Cryoablation of Renal Tumors: Tumor Size Predicts Disease Progression" by Pickersgill et al..</i> <i>Journal of Endourology</i> , 2020, 34, 1218-1218.	1.1	0
12	Renal Mass Biopsy: Future Trends and Developments. , 2020, , 195-207.		0
13	Surveillance after prostate focal therapy. <i>World Journal of Urology</i> , 2019, 37, 397-407.	1.2	63
14	Diagnosis and Management of Local Recurrence After Prostate Focal Therapy: Challenges and Solutions. <i>European Urology Oncology</i> , 2019, 2, 539-540.	2.6	1
15	Salvage Prostate Cryoablation for the Management of Local Recurrence After Primary Cryotherapy: A Retrospective Analysis of Functional and Intermediate-Term Oncological Outcomes Associated With a Second Therapeutic Freeze. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e831-e836.	0.9	12
16	Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. <i>Cancer</i> , 2019, 125, 3025-3032.	2.0	3
17	Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging. <i>BMC Urology</i> , 2019, 19, 127.	0.6	10
18	Reduced Core Targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging - transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies " An alternative template for prostate fusion biopsy. <i>European Journal of Radiology</i> , 2019, 110, 7-13.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Racial disparities in radium-223 treatment in a large real-world population.. Journal of Clinical Oncology, 2019, 37, 268-268.	0.8	1
20	Radium-223 treatment patterns in a large real-world population.. Journal of Clinical Oncology, 2019, 37, 190-190.	0.8	0
21	Defeating Cancersâ€™ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancerâ€™s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome. Technology in Cancer Research and Treatment, 2018, 17, 153303381876220.	0.8	18
22	New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer?. Abdominal Radiology, 2018, 43, 702-712.	1.0	15
23	Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate. Clinical Genitourinary Cancer, 2018, 16, e477-e482.	0.9	4
24	Three-dimensional localization and targeting of prostate cancer foci with imaging and histopathologic correlation. Current Opinion in Urology, 2018, 28, 506-511.	0.9	4
25	Effect of blood transfusions on oncological outcomes of surgically treated localized renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 362.e1-362.e7.	0.8	10
26	Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation. Journal of Endourology, 2017, 31, 497-501.	1.1	5
27	New advances in focal therapy for early stage prostate cancer. Expert Review of Anticancer Therapy, 2017, 17, 737-743.	1.1	16
28	Body mass index and the clinicopathological characteristics of clinically localized renal massesâ€™ An international retrospective review. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 459.e1-459.e5.	0.8	10
29	Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. Cancer, 2017, 123, 4122-4129.	2.0	15
30	New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. European Urology, 2017, 71, 17-34.	0.9	232
31	Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology. International Journal of Urology, 2017, 24, 137-143.	0.5	9
32	Expanding thermal ablation to the â€˜intermediate-sizedâ€™ renal mass: clinical utility in T1b tumors. Translational Andrology and Urology, 2017, 6, 127-130.	0.6	5
33	Prostate Cryotherapy. , 2017, , 273-285.		1
34	Pathologic Rationale for Focal Therapy of Prostate Cancer: Elucidating Tumor Characteristics and Biology. Current Clinical Urology, 2017, , 85-104.	0.0	0
35	Comparison between 3D ARFI imaging and mpMRI in detecting clinically-significant prostate cancer lesions. , 2016, , .		1
36	Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. Journal of Endourology, 2016, 30, 43-48.	1.1	30

#	ARTICLE	IF	CITATIONS
37	Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results. <i>European Urology</i> , 2016, 69, 116-128.	0.9	103
38	A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate. <i>Prostate</i> , 2015, 75, 1447-1453.	1.2	13
39	Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting. <i>European Urology</i> , 2015, 67, 771-777.	0.9	206
40	Current Trends and New Frontiers in Focal Therapy for Localized Prostate Cancer. <i>Current Urology Reports</i> , 2015, 16, 35.	1.0	12
41	Definitions and Principles of Focal Therapy. , 2015, , 19-28.		1
42	Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. <i>BJU International</i> , 2014, 114, 698-707.	1.3	42
43	How to select the right patients for focal therapy of prostate cancer?. <i>Current Opinion in Urology</i> , 2014, 24, 203-208.	0.9	17
44	Psychosocial Trajectories of Men Monitoring Prostate-Specific Antigen Levels Following Surgery for Prostate Cancer. <i>Oncology Nursing Forum</i> , 2014, 41, 361-368.	0.5	5
45	The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 732-751.	0.9	298
46	Small renal mass biopsy—how, what and when: report from an international consensus panel. <i>BJU International</i> , 2014, 113, 854-863.	1.3	98
47	Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1292-1299.	0.8	80
48	Combined cryotherapy and external beam radiation therapy for the treatment of intermediate-risk localized prostate cancer: A case series. <i>Case Reports in Clinical Medicine</i> , 2014, 03, 47-51.	0.1	0
49	Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other. <i>Oncology</i> , 2014, 28, 950-C3.	0.4	7
50	Short-term Functional Outcomes and Complications Associated With Transperineal Template Prostate Mapping Biopsy. <i>Urology</i> , 2013, 82, 166-170.	0.5	30
51	Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <math>\leq 2.5</math> ng/ml and 2.5–4 ng/ml. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1527-1532.	0.8	4
52	Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study. <i>BJU International</i> , 2013, 112, 526-530.	1.3	30
53	Pathologic Basis for Focal Therapy: Understanding Cancer Grade, Volume, and Spatial Location. , 2013, , 53-71.		0
54	Refining treatment for the men who need it: lessons from the PIVOT trial. <i>Translational Andrology and Urology</i> , 2013, 2, 82-4.	0.6	0

#	ARTICLE	IF	CITATIONS
55	The state of prostate MRI in 2013. <i>Oncology</i> , 2013, 27, 262-70.	0.4	32
56	Contrast Enhancement on Computed Tomography After Renal Cryoablation: An Evidence of Treatment Failure?. <i>Journal of Endourology</i> , 2012, 26, 330-335.	1.1	29
57	Preoperative Predictors of Pathologic Stage T2a in Low-Risk Prostate Cancer: Implications for Focal Therapy. <i>Urologia Internationalis</i> , 2012, 89, 296-300.	0.6	2
58	Ideal candidates for focal therapy. <i>Nature Reviews Urology</i> , 2012, 9, 12-13.	1.9	0
59	Prostate cancer treatment unblinded. <i>Lancet Oncology</i> , The, 2012, 13, 567-568.	5.1	3
60	Rationale for Percutaneous Biopsy and Histologic Characterisation of Renal Tumours. <i>European Urology</i> , 2012, 62, 491-504.	0.9	200
61	Predicting biopsy-proven prostate cancer recurrence following cryosurgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 391-395.	0.8	14
62	Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 21-25.	0.8	14
63	<sup>111</sup> In-capromab pentetide imaging using hybrid- <sup>13</sup> camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 150-154.	0.8	4
64	Focal Therapy of Prostate Cancer: Evidence-based Analysis for Modern Selection Criteria. <i>Current Urology Reports</i> , 2012, 13, 160-169.	1.0	22
65	Complications and postoperative events after cryosurgery for prostate cancer. <i>BJU International</i> , 2012, 109, 840-845.	1.3	23
66	Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. <i>BJU International</i> , 2012, 110, 942-948.	1.3	77
67	Focal Therapy: Prostate Hemiablation as the First Historical Treatment Model for Focal Therapy of Early Stage Prostate Cancer. , 2012, , 225-241.		1
68	Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database.. <i>Journal of Clinical Oncology</i> , 2012, 30, 34-34.	0.8	0
69	African American race to predict for earlier failure of active surveillance: Results from the Duke Prostate Center.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4670-4670.	0.8	0
70	Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 166-170.	0.8	41
71	Clinical predictors of renal mass pathological features. <i>BJU International</i> , 2011, 107, 735-740.	1.3	38
72	Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. <i>BJU International</i> , 2011, 108, 1074-1085.	1.3	84

#	ARTICLE	IF	CITATIONS
73	THE ROLE OF TRANSRECTAL SATURATION BIOPSY IN TUMOUR LOCALIZATION: PATHOLOGICAL CORRELATION AFTER RETROPUBIC RADICAL PROSTATECTOMY AND IMPLICATION FOR FOCAL ABLATIVE THERAPY. BJU International, 2011, 108, 371-371.	1.3	1
74	Treatment of Localised Renal Cell Carcinoma. European Urology, 2011, 60, 662-672.	0.9	198
75	Cigarette Smoking Is Associated With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2011, 29, 2027-2031.	0.8	75
76	Renal Function Outcomes After Laparoscopic Renal Cryoablation. Journal of Endourology, 2011, 25, 1287-1291.	1.1	18
77	Focal Cryotherapy for Prostate Cancer. Current Urology Reports, 2010, 11, 147-151.	1.0	24
78	Predicting Occult Multifocality of Renal Cell Carcinoma. European Urology, 2010, 58, 118-126.	0.9	26
79	Focal Therapy for Prostate Cancer: Possibilities and Limitations. European Urology, 2010, 58, 57-64.	0.9	95
80	Complications of Laparoscopic and Percutaneous Renal Cryoablation in a Single Tertiary Referral Center. European Urology, 2010, 58, 142-148.	0.9	36
81	Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades. Cancer, 2010, 116, 4711-4717.	2.0	23
82	Acoustic Radiation Force Impulse Imaging of Human Prostates Ex Vivo. Ultrasound in Medicine and Biology, 2010, 36, 576-588.	0.7	63
83	Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU International, 2010, 105, 1089-1092.	1.3	51
84	Pathological T2 subdivisions as a prognostic factor in the biochemical recurrence of prostate cancer. BJU International, 2010, 106, 1623-1627.	1.3	15
85	Minimally invasive surgery using ablative modalities for the localized renal mass. International Journal of Urology, 2010, 17, 215-227.	0.5	20
86	Characterizing Stiffness of Human Prostates Using Acoustic Radiation Force. Ultrasonic Imaging, 2010, 32, 201-213.	1.4	53
87	Prostate Biopsy in Selecting Candidates for Hemiablative Focal Therapy. Journal of Endourology, 2010, 24, 849-853.	1.1	13
88	Morphology of hypoxia following cryoablation in a prostate cancer murine model: Its relationship to necrosis, apoptosis and, microvessel density. Cryobiology, 2010, 61, 148-154.	0.3	17
89	Tumor Size and Endophytic Growth Pattern Affect Recurrence Rates After Laparoscopic Renal Cryoablation. Urology, 2010, 75, 307-310.	0.5	36
90	Analysis of Urinary Function Using Validated Instruments and Uroflowmetry After Primary and Salvage Prostate Cryoablation. Urology, 2010, 76, 1258-1265.	0.5	18

#	ARTICLE	IF	CITATIONS
91	Role of Vitamin D3 as a Sensitizer to Cryoablation in a Murine Prostate Cancer Model: Preliminary In Vivo Study. <i>Urology</i> , 2010, 76, 764.e14-764.e20.	0.5	23
92	Prostate Cancer: An Evolving Paradigm. <i>Journal of Endourology</i> , 2010, 24, 805-809.	1.1	7
93	Contemporary Results of Focal Therapy for Prostate Cancer Using Cryoablation. <i>Journal of Endourology</i> , 2010, 24, 827-834.	1.1	21
94	Recent advances in focal therapy of prostate and kidney cancer. <i>F1000 Medicine Reports</i> , 2010, 2, .	2.9	0
95	Prostate Focal Therapy. , 2010, , 105-113.		0
96	Pathologic basis of focal therapy for early-stage prostate cancer. <i>Nature Reviews Urology</i> , 2009, 6, 205-215.	1.9	59
97	Utility of a 3-Dimensional Transrectal Ultrasound-guided Prostate Biopsy System for Prostate Cancer Detection. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 99-103.	0.8	5
98	Patient selection for hemiablativ focal therapy of prostate cancer. <i>Cancer</i> , 2009, 115, 2104-2110.	2.0	57
99	Utilization of <sup>111</sup> In- $\alpha$ Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary <i>in situ</i> therapy. <i>International Journal of Urology</i> , 2009, 16, 971-975.	0.5	10
100	Focal Therapy for Prostate Cancer Is a Reasonable Treatment Option in Properly Selected Patients. <i>Urology</i> , 2009, 74, 726-730.	0.5	37
101	Changes in Gleason Score Grading and Their Effect in Predicting Outcome After Radical Prostatectomy. <i>Urology</i> , 2009, 74, 1090-1093.	0.5	48
102	Use of <sup>111</sup> In-Capromab Pendetide Immunoscintigraphy to Image Localized Prostate Cancer Foci Within the Prostate Gland. <i>Journal of Urology</i> , 2009, 182, 938-948.	0.2	11
103	Focal Targeted Therapy Will Be a Future Treatment Modality for Early Stage Prostate Cancer. <i>European Urology Supplements</i> , 2009, 8, 424-432.	0.1	13
104	Nerve-sparing focal cryoablation of prostate cancer. <i>Current Opinion in Urology</i> , 2009, 19, 182-187.	0.9	23
105	Prostate cancer: the new landscape. <i>Current Opinion in Urology</i> , 2009, 19, 154-160.	0.9	26
106	Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. <i>Drug Design, Development and Therapy</i> , 2009, 3, 27-40.	2.0	25
107	Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: Implications for unilateral ablative therapy. <i>Prostate</i> , 2008, 68, 1380-1386.	1.2	64
108	Use of Local <sup>111</sup> In-Capromab Pendetide Scan Results to Predict Outcome After Salvage Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 358-361.	0.4	22

#	ARTICLE	IF	CITATIONS
109	Urothelial Sloughing with Obstruction After Laparoscopic Cryoablation of Small Renal Carcinoma in Solitary Kidney. <i>Urology</i> , 2008, 72, 716.e1-716.e2.	0.5	2
110	Persistent Contrast Enhancement Several Months after Laparoscopic Cryoablation of the Small Renal Mass May Not Indicate Recurrent Tumor. <i>Journal of Endourology</i> , 2008, 22, 2433-2440.	1.1	35
111	Three-dimensional acoustic radiation force impulse (ARFI) imaging of human prostates in vivo. , 2008, , .		9
112	The Effect of Cryoablation on the Histologic Interpretation of Intraoperative Biopsy of Small Clear Cell Renal Carcinoma and Renal Oncocytoma. <i>Journal of Endourology</i> , 2008, 22, 1617-1622.	1.1	10
113	Avoiding surgery in prostate cancer patients with low-risk disease. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 25-36.	0.2	3
114	Focal therapy for prostate cancer. <i>Current Opinion in Urology</i> , 2008, 18, 269-274.	0.9	53
115	Zoledronic acid in the management of metastatic bone disease. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 261-268.	0.9	60
116	From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer. <i>Oncology</i> , 2008, 22, 900-6; discussion 906-7, 914.	0.4	4
117	Analysis of Laterality and Percentage of Tumor Involvement in 1386 Prostatectomized Specimens for Selection of Unilateral Focal Cryotherapy. <i>Technology in Cancer Research and Treatment</i> , 2007, 6, 91-95.	0.8	36
118	Short Term Clinical Outcome after Laparoscopic Cryoablation of the Renal Tumor $\hat{a}$ % 3.5 cm. <i>Technology in Cancer Research and Treatment</i> , 2007, 6, 621-624.	0.8	14
119	Financial Comparative Analysis of Minimally Invasive Surgery to Open Surgery for Localized Prostate Cancer: A Single-Institution Experience. <i>Urology</i> , 2007, 69, 311-314.	0.5	78
120	Short-Term Cancer Control After Primary Cryosurgical Ablation for Clinically Localized Prostate Cancer Using Third-Generation Cryotechnology. <i>Urology</i> , 2007, 70, 117-121.	0.5	58
121	Prostate Cancer Laterality Does Not Predict Prostate-Specific Antigen Recurrence After Radical Prostatectomy. <i>Urology</i> , 2007, 70, 1141-1145.	0.5	24
122	Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. <i>Cancer</i> , 2007, 110, 906-910.	2.0	130
123	Current Status of Minimally Invasive Ablative Techniques in the Treatment of Small Renal Tumours. <i>European Urology</i> , 2007, 51, 328-336.	0.9	67
124	Prostatic abscess as a delayed complication following cryosurgery for primary prostate cancer. <i>Canadian Journal of Urology</i> , 2007, 14, 3646-8.	0.0	3
125	Laparoscopic Ureteroureterostomy for Retrocaval Ureter. <i>European Urology Supplements</i> , 2006, 5, 466-469.	0.1	12
126	Update on cryotherapy for prostate cancer in 2006. <i>Current Opinion in Urology</i> , 2006, 16, 152-156.	0.9	60



#	ARTICLE	IF	CITATIONS
127	ProstaScint (Capromab Pendetide) Imaging Using Hybrid Gamma Cameraâ€“CT Technology. American Journal of Roentgenology, 2005, 184, 676-680.	1.0	35
128	Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology, 2005, 66, 1054-1059.	0.5	40
129	RENAL CRYOABLATION AND RADIO FREQUENCY ABLATION: AN EVALUATION OF WORST CASE SCENARIOS IN A PORCINE MODEL. Journal of Urology, 2005, 173, 2160-2165.	0.2	79
130	Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer, 2002, 94, 987-996.	2.0	86
131	Clinical utility of indium 111â€“capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer, 2002, 94, 987-996.	2.0	1
132	Management of small renal tumors: an overview. American Journal of Medicine, 2001, 110, 558-562.	0.6	62
133	Capromab Pendetide Imaging of Prostate Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2000, 15, 131-140.	0.7	55
134	Comparison of clinical staging algorithms and 111Indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer, 1999, 85, 1586-1592.	2.0	101
135	PROSTATE SPECIFIC ANTIGEN: A DECADE OF DISCOVERY-WHAT WE HAVE LEARNED AND WHERE WE ARE GOING. Journal of Urology, 1999, 162, 293-306.	0.2	530
136	LAPAROSCOPIC URETEROURETEROSTOMY FOR RETROCAVAL URETER. Journal of Urology, 1998, 160, 121-122.	0.2	40
137	Reappraisal of the Role of Human Chorionic Gonadotropin in the Diagnosis and Treatment of the Nonpalpable Testis: A 10-year Experience. Journal of Urology, 1996, 156, 804-806.	0.2	24
138	Intraoperative Sonography for the Evaluation and Management of Renal Tumors: Experience with 100 Patients. Journal of Urology, 1995, 154, 1676-1680.	0.2	73